Smith & Nephew(US:SNN)2025-02-25 14:04Financial Performance - FY 2024 revenue grew by 5.3% on an underlying basis[6], reaching $5.81 billion[79] - Trading profit margin expanded by 60bps to 18.1% in FY 2024[6, 82] - Q4 2024 total revenue reached $1.571 billion, with underlying revenue growth of 8.3%[50, 52] - Free cash flow increased significantly to $551 million in FY 2024, compared to $129 million in FY 2023[105] - The company reiterates its 2025 guidance, expecting around 5% underlying growth and a trading margin of 19.0-20.0%[8] Business Segment Performance - Orthopaedics revenue in Q4 2024 was $608 million, with underlying growth of 6.0%[51, 54] - Sports Medicine & ENT revenue in Q4 2024 was $494 million, with underlying growth of 7.8%[51, 65] - Advanced Wound Management (AWM) revenue in Q4 2024 was $469 million, with underlying growth of 12.2%[51, 70] Strategic Initiatives - The 12-Point Plan is driving financial improvements and is on track[5, 113] - Gross run-rate savings of approximately $210 million were achieved by the end of 2024[91] - The company expects ROIC to exceed the cost of capital in 2025, projecting it to be greater than 8.5%[15, 46]